The Challenge of Conventional Stopper Coatings

Modern pharmaceutical manufacturing faces significant hurdles regarding drug-container interactions. Specifically, traditional vial stopper coatings like polydimethylsiloxane often shed particles into liquid formulations. These particles may compromise the quality and safety of delicate protein-based drugs. Consequently, researchers investigated a new method using aerosol-assisted cold plasma. This innovative process deposits a poly(MPC-co-BMA) copolymer directly onto the elastomeric stoppers.

Innovative Cold Plasma Deposition for Vial Stopper Coatings

Moreover, the study used a robust factorial design to optimize the vial stopper coatings and deposition parameters. Analysts employed advanced techniques like Scanning Electron Microscopy (SEM) and Raman imaging to verify the coating presence. Notably, the Raman imaging monitored the attenuation of inherent titanium dioxide signals from the stoppers. Therefore, they could map the coating uniformity without destroying the samples. This approach ensures that the protective layer remains consistent across the entire surface.

Enhanced Protein Compatibility Results

Furthermore, compatibility tests using a model bovine serum albumin formulation showed impressive results. The new poly(MPC-co-BMA) coating performed just as well as expensive commercial fluoropolymer options. Additionally, it significantly reduced the risk of polymer leaching compared to standard silicone oil treatments. Consequently, this aerosol-assisted cold plasma technique offers a promising future for pharmaceutical packaging. Ultimately, these findings provide a safer and more efficient alternative for storing high-value biologics.

Frequently Asked Questions

How do these new vial stopper coatings improve drug safety?

These coatings use a biomimetic copolymer that reduces protein adsorption and prevents the leaching of chemicals from the rubber stopper into the drug, maintaining product purity.

What is the advantage of using cold plasma for deposition?

Cold plasma allows for the application of high-performance coatings at room temperature. This protects heat-sensitive materials like rubber stoppers from damage during the manufacturing process.

Is poly(MPC-co-BMA) compatible with all protein drugs?

While initial tests with bovine serum albumin are promising, further studies are necessary to confirm compatibility with a broader range of specific therapeutic proteins and formulation buffers.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or professional manufacturing guidelines. Refer to the latest local and national guidelines for clinical practice.

References

Downey JD et al. Application of a phosphorylcholine-based copolymer, poly(MPC-co-BMA) on vial stoppers using a cold plasma deposition process. Pharm Dev Technol. 2026 Mar 29. doi: 10.1080/10837450.2026.2649645. PMID: 41904960.

Ishihara K. Biomimetic polymers with phosphorylcholine groups as biomaterials for medical devices. Front Bioeng Biotechnol. 2021;9:747231.

Cools P et al. Cold plasma surface modification of biodegradable polymers. Surface and Coatings Technology. 2018;344:630-643.